MicroRNAs asBiomarkers forDrug Resistanceand Response to Therapy in Cancers

A GOBIOM Case Study

The PurposeTo predict and analyze miRNAs indicative of treatment response and drug resistancein various cancers through heat-map analytics.

To identify the decisive miRNAs and position them as potential therapeutic targets inthe area of oncology.

miRNAs indicative of drug resistanceacross various oncology indications

miRNAs indicative of drug responseacross various oncology indications

Client Specification To identify miRNAs associated with the sensitivity of two cancers against an IND.

About the Client

THERAPEUTIC AREA

Oncology

LOCATION

Europe

Company

Biotech

The Excelra ApproachTo expedite, heat-map analytics was chosen in GOBIOM.

Heat-map analytics was used to draw forth the list of potential miRNAs indicative of response to the therapy and drug resistance by plotting miRNAs against various oncology related indications.

The list of drugs showing disease resistance was obtained by plotting drugs against various miRNAs across different indications.

miRNAs indicative of drug resistance across various drugs in oncology therapeutics

ERLOTIN

IB

GEFITINIB

CISPLATIN

5-FLUOROU..

OXALIPLATIN

PEMETRE..

GEMCITAB..

CARBOPLA..

CAPECITAB..

PREDNIS..

5-AZA-2’-D

E..

HYDROXYC..

1,25-DIH

YD..

ESTRADIOL-.

.

AUY-922

ATORVAST..

TADALAFIL

ETHANOL

TRICHOSTA..

MYCOPHEN..

NETAZEPID

E

CURCUMIN

RITUXIMAB

2,3-BIS(4-HY..

TRASTUZU..

4,4’,4’’-(4-PR..

TESTOSTER..

ACTIVIN A

LAPATINIB

PACLITAXEL

METHYLPR..

5-AZA-D

C

EBASTINE

BXL-0124

VORINOS..

NATALIZU..

GENISTEIN

ZEBULARINE

Y-27632

TAMOXIFEN

TEMOZOLO..

DOCOSAHE..

ANASTROZ..

CYCLOPHO..

TRIPTERYGI..

4-NITROQUI..

ROCILETINIB

PEGINTERF..

CETUXIMAB

CECOMBIN

MICRORNA 21MICRORNA 146AMICRORNA 127B

MICRORNA 17MICRORNA 20AMICRORNA 30CMICRORNA 32..MICRORNA 222MICRORNA 27A

MICRORNA 372..MICRORNA 769..MICRORNA 4791MICRORNA 3196MICRORNA 744..MICRORNA 585..MICRORNA 548..MICRORNA 4796

MICRORNA 103MICRORNA 138..MICRORNA 503..MICRORNA 4803MICRORNA 1469MICRORNA 16-1..MICRORNA 3153MICRORNA 125B

MICRORNA 205MICRORNA 34AMICRORNA 221MICRORNA 10B

MICRORNA 181AMICRORNA 17-9..

MICRORNA 152MICRORNA 20BMICRORNA 30A

MICRORNA 224..MICRORNA 196B

MICRORNA 424MICRORNA 210

MICRORNA21

Breast

Can..Lu

ng Cancer..

Pancreatic

C..Pro

state

Ca..Colore

ctal C

..Gastr

ic (Sto

..)Hepato

cellu

l..Recta

l Can..

Esophageal..

Lung Cance

rLe

ukem

ia, A..

Head and N..

Colon Can..Kidney (R

en..Cerv

ical C

a..Gllio

blastom

..Le

ukem

ia, C..

Ovarian Can..

Myelom

a, M..

Oral Cance

rMantle

Cell..Bladder C

an..

MICRORNA 200CMICRORNA 34AMICRORNA 221MICRORNA 205MICRORNA 210MICRORNA 27AMICRORNA 20A

MICRORNA 181AMICRORNA 200A-S...

MICRORNA 17MICRORNA 222MICRORNA 27B

MICRORNA 17-92 CL...MICRORNA 17-92 CL...

MICRORNA 10BMICRORNA 125B

MICRORNA -7BMICRORNA L 3196

MICRORNA 30BMICRORNA 146A

MICRORNA 19AMICRORNA 30C

MICRORNA 138-2-3PMICRORNA 769-3PMICRORNA 548AQ..

MICRORNA 103MICRORNA 1469MICRORNA 4791MICRORNA 20B

MICRORNA 200BMICRORNA 585-3PMICRORNA 372-3P

MICRORNA 4796MICRORNA 4803

MICRORNA 16-1-3PMICRORNA 503-3P

MICRORNA 3153MICRORNA 138

MICRORNA 744-5PMICRORNA 345MICRORNA 198

MICRORNA 29MICRORNA 612MICRORNA 30AMICRORNA 218

MICRORNA 196BMICRORNA 424

MICRORNA 301A

MICRORNA 21MICRORNA 155

MICRORNA 200CMICRORNA 221MICRORNA 205MICRORNA 210MICRORNA 375

MICRORNA 31MICRORNA 145MICRORNA 143MICRORNA 122MICRORNA 18AMICRORNA 182MICRORNA 20A

MICRORNA 25MICRORNA 16MICRORNA 22

MICRORNA LE..MICRORNA 18..MICRORNA 20..MICRORNA 29C

MICRORNA 17MICRORNA 222MICRORNA 326MICRORNA 27BMICRORNA 12..MICRORNA 30BMICRORNA 19AMICRORNA 19..MICRORNA LE..MICRORNA 451MICRORNA 92A

MICRORNA 1MICRORNA 29AMICRORNA 19..MICRORNA 18BMICRORNA 20BMICRORNA 378MICRORNA 195MICRORNA 30CMICRORNA 217MICRORNA 124

MICRORNA 31-3PMICRORNA 133B

Breast

Can..

Lung Cance

r..

Prosta

te Ca..

Prosta

te Ca..

Pancreatic

C..

Rectal C

an..

Hepatoce

llul..

Gastric

(Sto..

Lung Cance

r

Colon Can..

Head and N..

Giloblasto

m..

Esophageal..

Kidney (Ren..

Cervica

l Ca..

Oral Cance

r

Bladder Can..

Excelra’s Contribution

The miRNAs associated with the sensitivityof an IND may be used as a biomarker to

predict a response.Targets and major functions impacted by

the miRNAs could be identified.

Predicted miRNAs to categorizecancers into drug-sensitiveand/or resistant buckets.

Further ranked cancers as pertheir drug sensitivity scores.

Few relevant genes andtheir expression pattern

were also identified.

www.excelra.com

For more information, visit https://www.excelra.com/translational/#gobiom

About Excelra

Excelra's data and analytics solutions empower innovation in life sciences across the value chain from discovery to market.The Excelra Edge comes from a seamless amalgamation of proprietary curated data assets, deep domain expertise and data science. The company's multifaceted teams harmonize and analyse large volumes of disparate unstructured data using cutting-edge technologies. We galvanize data-driven decisions to unlock operational efficiencies to accelerate drug discoveryand development. Over the past 18 years, Excelra has been the preferred data and analytics partner to over 90 global clients, including 15 of the top 20 large Pharma.

marketing@excelra.com

Excelra’s Service Portfolio

Discovery

Data Science Driven Drug Discovery

Target Identification

Target Dossier Services

Chemistry Curation Services

Biomarker Discovery

Drug Repositioning

Life Cycle Management

Systems Biology Informatics

Biology Curation Services

GOBIOM

Biomarker intelligence database

Precision Oncology Informatics

Clinical Pharmacology Clinical Trial Outcomes Database

Outcomes Research

Epidemiology Modelling

Economic Modelling

Value Evidence Communication

Enterprise Data Strategy

Enterprise Cloud Ops

Enterprise Digital Transformation

RWE & Big Data Realization

SLR & Meta-analysis

GOSTAR

Structure Activity Relationship database

Insights Data

Translational

Clinical

Value Evidence

TechnologySolutions